Skip to content

Trial Summary

A Phase I Study of PCUR-101 in Combination with Androgen Directed Therapy in the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer

Acronym:

PELLFICURE

ACTRN/NCT /ethics:

NCT03137758

Scientific title:

A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

Sponsor / Cooperative group:

Pellficure Pharmaceuticals, Inc

Trial & Patient Characteristics

Cancer TypeProstate
Trial TypeTreatment
PhasePhase I
Age Range18 years and older
SexMale
Tumour Stream -
Cancer StageMetastatic or Widespread
Anticipated Start Date2017-07-24
Anticipated End Date2019-09-17

Participating Hospitals

HospitalCancer Research SA
Clinical Trial CoordinatorKelly Mead
Emailadmin@cancerresearchsa.com.au
Phone08 8359 2565
Principal InvestigatorDr Sarwan Bishnoi
Recruitment StatusRecruiting